| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:643-649.)
© 2005 American Heart Association, Inc.
Molecular Cardiology |
From INSERM U541, Hôpital Lariboisière, Paris, France.
Correspondence to Dr Stéphanie Lehoux, INSERM U541, Hôpital Lariboisière, 41, Boulevard de la Chapelle, 75010 Paris, France. E-mail lehoux{at}larib.inserm.fr
Received May 26, 2004; revision received October 13, 2004; accepted October 15, 2004.
| Abstract |
|---|
|
|
|---|
Methods and Results Using rabbit aortas maintained in organ culture for 24 hours, we found that focal adhesion kinase (FAK) was strongly activated by high intraluminal pressure (150 mm Hg), as evidenced by increased phosphorylation (P<0.01) of tyrosine residues Tyr-397 (3.06±0.17-fold), Tyr-407 (3.71±0.65-fold), Tyr-861 (1.92±0.33-fold), and Tyr-925 (2.41±0.39-fold), compared with 80 mm Hg controls. Immunohistochemistry showed positive staining for these phosphotyrosines in the endothelium and innermost smooth muscle cell layers. Total FAK phosphorylation was reduced in vessels at 150 mm Hg by treatment with the Src family kinase inhibitor PP2 or with the integrinextracellular matrix interactionblocking RGD peptide, attaining 1.75±0.22-fold and 2.00±0.19-fold, respectively (P<0.05), compared with 3.07±0.38-fold (P<0.001) in untreated vessels. PP2 prevented phosphorylation of Tyr-407 and Tyr-925, whereas RGD peptide abolished phosphorylation of Tyr-397 and Tyr-407. PP2 and RGD peptide also inhibited high pressureinduced binding of FAK with the effector Grb2 and blocked activation of extracellular regulated kinase (ERK) 1/2 in vessels at 150 mm Hg. In contrast, 10% cyclic stretch in aortas did not induce significant FAK phosphorylation relative to nonpulsatile controls. Furthermore, although ERK1/2 was activated in vessels exposed to pulsatility, it was not blocked by PP2 or RGD peptide treatment.
Conclusions Our results demonstrate that (1) steady and cyclic modes of stretch are transduced differently in the aorta, the former implicating FAK, the latter not, and (2) Src and integrins are involved in steady pressureinduced FAK.
Key Words: mechanics signal transduction remodeling hypertension arteries
| Introduction |
|---|
|
|
|---|
Vascular cells possess a variety of mechanosensors capable of perceiving and transmitting external signals to the intracellular compartment (reviewed in Lehoux and Tedgui3). These include the integrins, which bind extracellular matrix proteins and interact functionally with cytoskeletal elements and associated proteins within the cell. In VSMCs in culture, creation of new integrinextracellular matrix interactions appears to be a key component of the mechanotransduction process, because the RGD peptide that prevents integrinextracellular matrix bridging also inhibit the VSMC proliferative response to cyclic strain.4 Mechanical signaling cascades also include FAK (focal adhesion kinase), which is recruited to focal adhesion complexes formed on integrin stimulation. FAK activation has been shown to occur in endothelial cells or VSMCs exposed to cyclic stretch,5,6 and in resistance arteries, acute steady stretch induces phosphorylation of FAK at Tyr-397.7
Downstream signaling pathways elicited by mechanical factors and transmitted through FAK may include the extracellular signalregulated kinase (ERK) 1/2 cascade. Indeed, in fibroblasts, cyclic strain induction of ERK1/2 is significantly inhibited if cells are transfected with a mutant form of FAK.8 Similarly, shear stress activates ERK1/2 in endothelial cells, but this response is attenuated in cells expressing a dominant-negative FAK mutant.9 Although both cyclic and steady modes of stretch are known to activate ERK1/2 in vessels1012 and in VSMCs,13 the role of FAK in this ERK1/2 activation has not been established. Interestingly, the pathways of vascular ERK1/2 activation by steady and pulsatile stretch appear to differ, the former being sensitive to Src family kinase inhibition,10 the latter not,11 so studying FAK activity in vessels exposed to these 2 forms of strain may also yield distinct results.
Signaling pathways induced by stretch are dependent not only on the type of matrix on which cells are plated13 and on specific integrinmatrix interactions14 but also on the spatial organization of VSMCs in culture (3-dimensional versus a 2-dimensional environment)15 as well as their differentiation state.16 Although these specificities are interesting with regard to transduction pathway identification, they also imply that observations made in cultured cells may differ from what occurs in whole vessels. Therefore, in the present study, we evaluated and compared the effects of pulsatile and steady stretch on FAK activity in whole vessels in organ culture. Furthermore, we sought to elucidate how FAK activation processes contribute to the mechanically induced ERK1/2 signaling cascade under these conditions.
| Methods |
|---|
|
|
|---|
Experimental Protocol
Each aorta was divided into 3 segments that were arbitrarily assigned different culture conditions, such that for each complete aorta there was 1 nonpulsatile segment at 80 mm Hg (the 100% setting for phosphorylation, coprecipitation, or activity assays) and 2 segments either at high pressure (150 mm Hg) or at 10% pulsatility. Pulsatility (0.75 Hz) was applied with a pump that produced a 10% change in vessel diameter at each pulse, as illustrated earlier.10 At such settings, the pump produced a flow of 40 mL/min, corresponding to a negligible shear stress (
0.4 dyne/cm2). In comparison, control nonpulsatile vessels were perfused at 0.2 mL/min to ensure renewal of culture medium within the aorta but to avoid any pulsatility (0.5%) effects. The average pressure in the pulsatile segments was set at 80 mm Hg, but it effectively ranged from 70 to 90 mm Hg at each pulse. In some experiments, RGD peptide (Gly-Arg-Gly-Asp-Ser-Pro, 0.4 mg/mL), RGE peptide (Gly-Arg-Glu-Ser, 0.4 mg/mL), or PP2 (10 µmol/L) was added to the culture medium at the onset of the experiments in both intraluminal and extraluminal compartments. For short-term experiments, vessels were stabilized for 90 minutes at 80 mm Hg, and then intraluminal pressure was elevated to 150 mm Hg and maintained for 5 to 20 minutes at this pressure before rapid removal and processing.
Tissue Extraction
Vessel segments were pulverized in LN2. The powders were resuspended in ice-cold lysis buffer (20 mmol/L Tris-HCl pH 7.5, 5 mmol/L EGTA, 150 mmol/L NaCl, 20 mmol/L glycerophosphate, 10 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1% Triton X-100, 0.1% Tween-20, and protease inhibitor tablets [Boehringer]) at a ratio of 0.3 mL/10 mg wet weight. Extracts were incubated on ice for 15 minutes and then centrifuged (14 000g, 15 minutes, 4°C). The detergent-soluble supernatant fractions were retained, and protein concentrations in samples were equalized by a Bio-Rad protein assay.
Immunoblotting
Lysates containing equal amounts of protein (30 µg) were electrophoresed on polyacrylamide gels and transferred to nitrocellulose membranes. In some experiments, 30-µg protein samples were immunoprecipitated with anti-FAK antibodies (Transduction Laboratories) and protein A/G agarose (Santa Cruz) before electrophoresis. Membranes were probed with antiphospho-ERK1/2, anti-FAK (Transduction Laboratories), anti-ERK2, anti-Grb2 (Santa Cruz), or antiphospho-Tyr-397-, Tyr-407-, Tyr-576-, Tyr-577-, Tyr-861-, or Tyr-925-FAK antibodies (Biosource International). An enhanced chemiluminescence system was used as the detection method (Amersham).
FAK Activity
FAK was immunoprecipitated from 30-µg protein samples as indicated earlier. Immunoprecipitates were incubated with paxillin in kinase buffer (50 mmol/L HEPES pH 7.5, 10 mmol/L MnCl2, 10 mmol/L MgCl2, and 2 mmol/L NaF) containing [
32P]ATP and PP2 (10 µmol/L) for 20 minutes at 30°C. Kinase reactions were stopped by addition of 2x Laemmli buffer, and samples were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and visualized by autoradiography. After autoradiography, gel proteins were transferred onto a polyvinylidene difluoride membrane and probed with anti-FAK to confirm equal loading.
Immunohistochemistry
Vessel segments were embedded vertically in Tissu-Tek (Sakura), and cryosections (10 µm) from the 3 segments of each aorta were processed simultaneously. Sections were incubated with antiphospho-Tyr-397, Tyr-407, Tyr-861, and Tyr-925 antibodies. Immunostains were revealed by avidin-biotin horseradish peroxidase visualization systems (Vectastain ABC kit, Vector Laboratories).
Data Analysis
Results, indicating fold increases based on ratios of paired observations within rabbits, are expressed as mean±SE. Data were analyzed by 1-way (for comparison of different intraluminal pressure groups) or 2-way (to evaluate effects of inhibitor treatments) ANOVA. When ANOVA analysis yielded significant results, comparisons were done with Bonferronis test. Statistical significance was accepted for values of P<0.05.
| Results |
|---|
|
|
|---|
|
A more detailed assessment of FAK activation with the use of site-specific phosphotyrosine antibodies (Figure 1B) revealed that phosphorylation of Tyr-397, Tyr-407, Tyr-861, and Tyr-925 was enhanced in aortic segments kept at 150 mm Hg versus vessels at 80 mm Hg. In fact, FAK activation was incremental, because vessels maintained at 120 mm Hg also showed enhanced FAK phosphorylation, though to a lesser degree than arteries at 150 mm Hg (Data Supplement Figure I). Furthermore, FAK tyrosine residue phosphorylation was also enhanced in an in vivo model of acute, angiotensin IIinduced hypertension (Data Supplement Figure I). Conversely, the phosphorylation state of Tyr-576 and Tyr-577 did not differ between vessels maintained at either pressure condition, nor did total FAK content (Figure 1). Vessels stimulated by cyclic stretch displayed enhanced phosphorylation of Tyr-861 only when matched with nonpulsatile aortas.
Kinetics of FAK Activation
We have previously demonstrated that pressure-dependent ERK1/2 activation is biphasic, characterized by an acute peak and a second, more prolonged induction.10 Here, we confirmed that ERK1/2 activity was maximal (3.20±0.09-fold, P<0.001) 10 minutes after onset of high intraluminal pressure and declined at 20 minutes, corresponding to the early activation phase (Figure 2). Interestingly, the kinetics of FAK phosphorylation slightly preceded ERK1/2 activation: Phosphorylation of FAK on Tyr-397, Tyr-861, and Tyr-925 was maximal within 5 minutes (by 2.23±0.32-, 1.97±0.41-, and 2.46±0.46-fold, respectively; P<0.05), remained elevated at 10 minutes, and then fell to baseline levels at 20 minutes. These observations concur with our hypothesis of a stretch-induced signaling pathway involving sequential activation of FAK and ERK1/2.
|
IntegrinExtracellular Matrix Interactions and Src Family Kinases Participate in Pressure-Induced FAK Phosphorylation
To characterize the pathways of FAK activation induced by steady high pressure, vessel segments were maintained in culture for 24 hours at 150 mm Hg in the presence of a Src family kinase inhibitor (PP2) or RGD peptide. Figure 3A shows that both treatments partially reduced total FAK phosphorylation in vessels; FAK phosphorylation only reached 1.75±0.22-fold of 80 mm Hg controls in PP2-treated aortas and 2.00±0.19-fold in RGD-treated aortas, compared with 3.07±0.38-fold in untreated vessels. Control RGE peptide did not affect total FAK phosphorylation.
|
Elevated total FAK phosphorylation in vessels at high pressure was correlated with increased kinase activity (2.26±0.45-fold, P<0.01), as measured by phosphorylation of paxillin (Figure 3B), despite the fact that residues Tyr-576 and Tyr-577 were not phosphorylated in these conditions, as shown earlier. In comparison, although inhibition of FAK phosphorylation by PP2 or RGD peptide was only partial, these treatments completely prevented FAK activity.
The effects of PP2 and RGD were examined in greater detail by focusing on the tyrosine residues shown in Figure 1 to be specifically phosphorylated in vessels at high pressure. In untreated controls, phosphorylation of Tyr-397, Tyr-407, Tyr-861, and Tyr-925 reached 3.06±0.17-fold (P<0.001), 3.71±0.65-fold (P<0.01), 1.92±0.33-fold (P<0.01), and 2.41±0.39-fold (P<0.01) of controls (80 mm Hg), respectively. Phosphorylation of Tyr-407 and Tyr-925 was abolished in vessels at 150 mm Hg treated with PP2, whereas RGD peptide prevented phosphorylation of Tyr-397 and Tyr-407 (Figure 4). Interestingly, neither treatment interfered with phosphorylation of Tyr-861, which remained elevated in all vessels at high pressure. Similarly, pulsatility-induced phosphorylation of Tyr-861 was also impervious to PP2 or RGD peptide treatment (data not shown).
|
To localize FAK activation sites within the arterial wall, histological sections of vessels were probed with antibodies corresponding to the pressure-dependent phosphotyrosines (Figure 5). As expected, little staining was detected in aortas maintained at 80 mm Hg. However, vessels at 150 mm Hg showed positive staining for Tyr-397, Tyr-407, Tyr-861, and Tyr-925. Staining was most marked in the innermost layer of the aorta, corresponding to the area of greatest strain. In vessels treated with PP2 or RGD peptide, staining for Tyr-407 and Tyr-925 or for Tyr-397 and Tyr-407 was reduced, respectively, in agreement with immunoblot observations, whereas Tyr-861 staining was not abated. Furthermore, only staining for Tyr-861 was enhanced in pulsatile vessels.
|
FAK Associates With Grb2 in Vessels at High Pressure
To establish a link between FAK phosphorylation and signaling events leading to ERK1/2 activation, the interaction of FAK with the downstream effector Grb2 was evaluated. As depicted in Figure 6, Grb2 coimmunoprecipitated with FAK exclusively in vessels exposed to steady, high, intraluminal pressure and not in aortas stimulated by pulsatile pressure. In vessels at 150 mm Hg, the amount of Grb2 found to coprecipitate with FAK was nearly doubled (1.86±0.13-fold, P<0.001) compared with vessels at 80 mm Hg. Furthermore, the interaction of Grb2 with FAK was no longer observed in vessels at 150 mm Hg treated with PP2 or with RGD peptide.
|
Differential Activation of ERK1/2 by Steady and Pulsatile Pressure
Finally, in untreated vessels, both high pressure and pulsatility induced ERK1/2, to 2.61±0.23 and 2.00±0.20-fold of controls, respectively (P<0.001; Figure 7). ERK1/2 activation by steady pressure was completely abolished in aortas cultured in the presence of PP2 or RDG peptide, whereas the same treatments failed to prevent ERK1/2 activation by pulsatile stretch (Figure 5). Hence, only ERK1/2 activation by high intraluminal pressure required Src family kinases and integrinextracellular matrix interaction. Moreover, the specificity of this pathway was demonstrated by the failure of PP2 or RGD peptide to prevent pressure-induced nuclear factor-
B pathway activation, measured by inhibitor-
B degradation (Data Supplement Figure II).
|
| Discussion |
|---|
|
|
|---|
Steady pressureinduced signaling has received little attention thus far. In one recent study, resistance arteries exposed to a sudden increment in intraluminal pressure showed increased phosphorylation of Src at 1 and 3 minutes but not at 5 minutes and Src-dependent FAK phosphorylation on Tyr-397 at 3 and 5 minutes.7 Our findings are in keeping with those results for acute pressure-induced FAK phosphorylation at this site but contrast in the sensitivity of Tyr-397 to Src kinase inhibition, which was absent in our case. This difference may be due to the nature of the vessels studied (resistance versus conductance arteries) or to the discrepancy in kinetics (5 minutes versus 24 hours). One particular interest of looking at signal transduction over 24 hours is that it may be a good indicator of pathways involved in long-term vascular remodeling rather than short-term regulatory processes.
Autophosphorylation of FAK at Tyr-397 activates a docking site for Src family kinases, which in turn can phosphorylate several other activation sites on FAK, including Tyr-925. Binding of Grb2 at this latter tyrosine launches a chain of events that culminate in ERK1/2 activation.18 In the present study, we went on to show that beyond Tyr-397, 3 other tyrosines on FAK are phosphorylated in vessels maintained at 150 mm Hg: Tyr-407, Tyr-861, and Tyr-925. Only Tyr-407 phosphorylation was inhibited by both RGD peptide and PP2, whereas phosphorylation of Tyr-397 was blocked by RGD peptide and that of Tyr-925 inhibited by PP2 only. So our findings imply that pressure-induced FAK phosphorylation involves 2 separate events: (1) integrinextracellular matrix interaction, driving recruitment of FAK to focal contacts at sites of integrin clustering and autophosphorylation at Tyr-397, and (2) Src family kinase activation, leading to phosphorylation of FAK at 2 more sites, Tyr-407 and Tyr-925. A previous study indicated that phosphorylation of Tyr-397 and Tyr-925 is required for FAK-Grb2 association; the actual Grb2 binding site was reported to encompass Tyr-925 only, but phosphorylation of Tyr-397 initiated the sequential binding of Src to FAK, leading to Tyr-925 phosphorylation.19 Here, however, Tyr-925 phosphorylation occurred in spite of RGD treatment that blocked Tyr-397 phosphorylation, but apparently phosphorylation of Tyr-925 alone was not sufficient to support FAK-Grb2 association and downstream ERK1/2 activation. Because coprecipitation of Grb2 with FAK was sensitive to both RGD peptide and PP2, as was phosphorylation of Tyr-407, our results suggest that this latter tyrosine may play a previously unsuspected role in transducing mechanical stimuli in the intact vessel. Our observation that steady pressuredependent activation of ERK1/2 was blocked by RGD peptide and PP2 further substantiates the dual role for integrins and Src in FAK-mediated signaling.
It is interesting that Tyr-576 and Tyr-577 were not phosphorylated in vessels at high pressure. These tyrosines lie in the activation loop of FAK, and their phosphorylation is classically required for full activation of the kinase.18 Nevertheless, an appreciable level of FAK activity could be detected in vessels at steady elevated pressure, as suggested by the downstream activation of ERK1/2 and confirmed by the activity assay with paxillin as a substrate.
On the other hand, the only FAK residue found to be phosphorylated not only in vessels at steady pressure but also in pulsatile aortas was Tyr-861. Intriguingly, although Tyr-861 was originally shown to be phosphorylated by Src,20 this did not appear to be the case in pressure-stimulated vessels, because phosphorylation state was unaffected by PP2 or by RGD peptide for that matter. Nevertheless, immunohistological staining revealed that phosphoTyr-861 distribution did not differ significantly from that of other tyrosines investigated, so that inhibitor penetration cannot be held accountable for this discrepancy. Perhaps differences in experimental models or species are at cause. Further studies will be needed to uncover mechanosensitive Tyr-861 activation pathways and downstream signaling cascades.
The present results outline a pathway for steady stretchinduced ERK1/2 activation involving FAK as an upstream mediator, both in short-term experiments and at 24 hours. Conversely, phosphorylation of Tyr-861 alone is clearly not sufficient to drive ERK1/2 activation in pulsatile vessels. However, in vitro cell cultures exposed to cyclic strain appear to respond differently as regards stretch-activated FAK phosphorylation or integrinextracellular matrixdependent ERK1/2 activation. For example, it was recently demonstrated that imposing cyclic stretch on ventricular myocytes induces Src-dependent FAK phosphorylation at Tyr-397 and Tyr-577.21 In a similar study, cyclic stretch was found to stimulate phosphorylation of FAK at Tyr-397 and Tyr-925 in cultured fibroblasts, along with activation of ERK1/2 and p38. Transfection of cells with inactive FAK mutants completely abolished cyclic stretchinduced p38 and strongly reduced ERK1/2 activation.22,23 Cyclic strain also triggered total FAK phosphorylation in endothelial cells.5 In SMCs, ERK1/2 was stimulated by vibrating ferromagnetic beads coated with fibronectin, vitronectin, or ß3-integrin but not by
2- or ß1-integrincoated beads,14 and cyclic stretch induced ERK1/2 in cells cultured on pronectin but not laminin.13 Differences between whole-vessel and cell culture experiments are not restricted to FAK-ERK1/2 signaling; numerous publications describe cyclic stretchactivated NF-
B in vascular cells (summarized in Lemarie et al24), but presently, although we demonstrated a FAK-independent, steady stretch activation of NF-
B, we found no evidence for activation of this pathway in pulsatile vessels. Several factors could account for the disparities between our observations and the aforementioned studies. Perhaps most important is the fact that vessels comprise cells within a 3-dimensional matrix environment, unlike the 2-dimension cell culture, which can influence vascular cell differentiation state and response to stimuli,15 as well as focal adhesion organization and FAK phosphorylation.25 Cells in culture, as used in previous experiments cited earlier, are bound to be dedifferentiated and, in the case of VSMCs, of a synthetic rather than contractile phenotype. Phenotype has been shown to influence ERK1/2 signaling in VSMCs exposed to pulse pressure,16 and it is likely to explain, at least in part, the contrasting responses to pulsatile stretch encountered in cultured cells and whole vessels. Of further consideration is extracellular matrix composition, which is complex and organized in native vessels and, as such, dictates the nature of new integrinmatrix protein interactions that can occur in response to stretch.
Nevertheless, distinguishing between pulsatile and steady stretch is important because in the whole vessel, these stimuli have very different outcomes. In the aorta, pulsatility is a physiological stimulus, given the rhythmic changes in pressure within this vessel imposed by the cardiac cycle. Hence, ERK1/2 activity observed in pulsatile segments presumably represents a basic level contributing to maintenance of vessel structure and function. In the case of a blood pressure increment, several morphological changes take place in the vessel wall, associated with thickening and rigidification of the vessel. Supplemental activation of ERK1/2 in this context, transmitted through FAK, may tip the balance toward a proliferative/hypertrophic SMC phenotype. The in vitro vascular cell experiments described earlier, typifying SMCs in a wounded vessel (such as after angioplasty), also point to a role for FAK-driven ERK1/2 activation in cell proliferation (driving restenosis). Blocking ERK1/2 would presumably prevent undesired SMC proliferation but may incur other phenotypic changes through inhibition of basal ERK1/2 activity. Our observations suggest that targeting Tyr-407 may be the single most specific way to maintain SMC quiescence in the vessel; on the contrary, it may prove beneficial to avoid hindering FAK phosphorylation at Tyr-861, which could be involved in other signaling pathways unrelated to ERK1/2.
In summary, our results show that high intraluminal pressure and pulsatile pressure are transduced differently in the vascular wall. Although both stimuli activate the ERK1/2 pathway, only in the case of steady stretch is FAK implicated as an upstream mediator; steady stretch is in fact a strong activator of FAK, acting through integrinextracellular matrix interaction and Src family kinase induction. Pulsatility, on the other hand, has very little impact on FAK phosphorylation in the whole vessel. These results emphasize key differences in vascular response to steady and pulsatile mechanical stresses and underscore the benefit of whole-vessel preparations in elucidating mechanotransduction pathways.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
regulates smooth muscle cell migration. FASEB J. 2003; 17: 21062108.[Medline]
[Order article via Infotrieve]
B: role in cell survival. Circ Res. 2003; 93: 207212.This article has been cited by other articles:
![]() |
F. Feihl, L. Liaudet, B. I. Levy, and B. Waeber Hypertension and microvascular remodelling Cardiovasc Res, May 1, 2008; 78(2): 274 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Billon, S. Lehoux, L. Lam Shang Leen, H. Laurell, C. Filipe, V. Benouaich, L. Brouchet, C. Dessy, P. Gourdy, A.-P. Gadeau, et al. The Estrogen Effects on Endothelial Repair and Mitogen-Activated Protein Kinase Activation Are Abolished in Endothelial Nitric-Oxide (NO) Synthase Knockout Mice, but Not by NO Synthase Inhibition by N-Nitro-L-arginine Methyl Ester Am. J. Pathol., March 1, 2008; 172(3): 830 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Albinsson, I. Nordstrom, K. Sward, and P. Hellstrand Differential dependence of stretch and shear stress signaling on caveolin-1 in the vascular wall Am J Physiol Cell Physiol, January 1, 2008; 294(1): C271 - C279. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Louis, A. Kakou, V. Regnault, C. Labat, A. Bressenot, J. Gao-Li, H. Gardner, S. N. Thornton, P. Challande, Z. Li, et al. Role of {alpha}1beta1-integrin in arterial stiffness and angiotensin-induced arterial wall hypertrophy in mice Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2597 - H2604. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Liu, C. M. Nelson, J. L. Tan, and C. S. Chen Cadherins, RhoA, and Rac1 Are Differentially Required for Stretch-Mediated Proliferation in Endothelial Versus Smooth Muscle Cells Circ. Res., August 31, 2007; 101(5): e44 - e52. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Albinsson and P. Hellstrand Integration of signal pathways for stretch-dependent growth and differentiation in vascular smooth muscle Am J Physiol Cell Physiol, August 1, 2007; 293(2): C772 - C782. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Safar and P. Lacolley Disturbance of macro- and microcirculation: relations with pulse pressure and cardiac organ damage Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H1 - H7. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Riou, B. Mees, B. Esposito, R. Merval, J. Vilar, D. Stengel, E. Ninio, R. van Haperen, R. de Crom, A. Tedgui, et al. High Pressure Promotes Monocyte Adhesion to the Vascular Wall Circ. Res., April 27, 2007; 100(8): 1226 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Kouri and O. Eickelberg Transforming Growth Factor-{alpha}, a Novel Mediator of Strain-Induced Vascular Remodeling Circ. Res., August 18, 2006; 99(4): 348 - 350. [Full Text] [PDF] |
||||
![]() |
C. A. Lemarie, P.-L. Tharaux, B. Esposito, A. Tedgui, and S. Lehoux Transforming Growth Factor-{alpha} Mediates Nuclear Factor {kappa}B Activation in Strained Arteries Circ. Res., August 18, 2006; 99(4): 434 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lehoux Redox signalling in vascular responses to shear and stretch Cardiovasc Res, July 15, 2006; 71(2): 269 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Kass Ventricular Arterial Stiffening: Integrating the Pathophysiology Hypertension, July 1, 2005; 46(1): 185 - 193. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||